THTülay Dilara Hattatoğlu

Tülay Dilara Hattatoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tülay Dilara Hattatoğlu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Can Large Language Models Support Family Communication in the Intensive Care Unit? A Comparative Accuracy Study

    by Mehmet Yıldırım, Tulay Dilara Demiray, Arda Ayten, Esat Kivanc Kaya

    Objective: Family members of patients admitted to the intensive care unit (ICU) frequently experience uncertainty, emotional distress, and significant informational needs. Communication gaps remain common in ICU practice due to time constraints and clinical complexity. Large language models (LLMs) may offer scalable support for patient–family information delivery; however, their performance in responding to real-world ICU family questions has not been systematically evaluated.Methods: This evaluator-blinded, cross-sectional study compared the accuracy of responses generated by five widely used LLMs (Claude Sonnet 4.0, ChatGPT 5.0, Gemini 2.5, Grok-4, and Sonar) to questions commonly asked by ICU family members. A standardized set of 25 questions was generated by prompting each model to list frequently asked ICU family questions. All questions were subsequently posed to all five models in blinded, independent sessions. Two intensive care medicine specialists independently rated response accuracy using a 6-point Likert scale. Inter-rater reliability was assessed using Cohen’s kappa. Differences between models were analyzed using the Friedman test with post-hoc Wilcoxon signed-rank tests.Results: A total of 125 responses were evaluated. Inter-rater agreement was moderate (Cohen’s κ = 0.56; overall agreement 73.6%). Accuracy scores differed significantly among models (p < 0.001). Claude Sonnet 4.0 achieved the highest mean accuracy score (5.66 ± 0.61), followed by ChatGPT 5.0, Gemini 2.5, and Sonar, with no statistically significant differences among these four models. Grok-4 demonstrated significantly lower accuracy compared with all other models (all p < 0.001).Conclusions: Most contemporary LLMs demonstrated high accuracy in answering questions commonly posed by ICU family members, although performance varied across platforms. Selected LLMs may serve as supportive tools to reinforce clinician–family communication; however, careful model selection, clinical oversight, and ethical safeguards are required before implementation in high-stakes intensive care settings.

  • Open Access

    Depression is the most significant independent predictor of fatigue in patients with primary Sjögren’s syndrome

    by Koray Ayar, Meliha Kasapoğlu Aksoy, Tülay Dilara Hattatoğlu, Büşra Yeşil

    Objectives: The study aimed to evaluate the level of fatigue and the relationship between mood, pain, fibromyalgia, insomnia, disease activity, and dryness with fatigue in primary Sjögren’s syndrome (PSS) patients. Patients and methods: In this case-control study, the participants were recruited between January 2021 and July 2021. Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F), pain DETECT questionnaire, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Insomnia Severity Index (ISI) were administered to 50 PSS patients (48 females, 2 males; mean age: 48.9±10.8 years; median age: 47 years; range, 29 to 71 years) and 60 healthy controls (HCs; 57 females, 3 males; mean age: 49.8±8.4 years, median age: 52 years; range, 32 to 72 years). In addition, EULAR Sjögren’s syndrome disease activity index (ESSPRI), EULAR Sjögren’s Syndrome Patient Reported Index (ESSDAI), pain thresholds, Schirmer tests, and whole unstimulated salivary flow rate measurements were determined in PSS patients. Independent predictors of fatigue (fatigue subscale scores


  • Open Access

    Prevalence of Hepatitis B virus serological groups in rheumatoid arthritis and association of previous hepatitis B virus infection with demographic data and parenteral therapies

    by Koray Ayar, Ali Asan, Orhan Onart, Mert Türk, Tulay Dilara Demiray

    Introduction: The aim of this study is to determine the frequency of Hepatitis b virus (HBV) serological groups in Rheumatoid arthritis (RA) and to compare the demographic characteristics and frequency of parenteral therapies between patient groups with and without previous HBV infection. Methods: Charts of RA patients were examined retrospectively. HBsAg, anti-HBc IgG, and anti-HBs test results were screened. All participants were divided into 3 serological groups (patients naive to HBV infection, previous HBV infection, vaccinated). Those with previous HBV infection were further divided into 3 serological subgroups (naturally immune, anti-HBc IgG positive only, chronic HBV infection). Findings were compared between RA patients with and without previous HBV infection. Results: Four hundred and fifty-one patients (female/male: 343/108) were included. The prevalence of patients naive to HBV infection, with previous HBV infection and vaccinated were 59.4%, 33.7%, and 6.9%, respectively. The prevalence of patients with naturally immune, anti-HBc IgG positive only, and chronic HBV infection were 25.7%, 4.4%, and 3.5%, respectively. Age in RA patients with and without previous HBV infection was 60.8±12.4 and 56.7±14.2 years, respectively(p


  • Evaluation of Hepatitis B Seroprevalence and Hepatitis B Reactivation Frequency in Rheumatology Patients Using Biological Drug Therapy

    by Koray Ayar, Ali Asan, Tülay Dilara Hattatoğlu, Koray AyarKurum BilgisiSağlık Bilimleri Üniversitesi, Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Romatoloji Kliniği, Bursa, Ali AsanKurum BilgisiSağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Tülay Dilara HattatoğluKurum BilgisiSağlık Bilimleri Üniversitesi, et al.

    Objective: The presence of hepatitis B virus (HBV) infection in patients using biological drug therapy may cause reactivation. There is insufficient data on the frequency of HBV reactivation, especially after the use of new biological drugs such as tofacitinib, tocilizumab, and secukinumab. This study aims to examine HBV seroprevalence in rheumatology patients using biological drug therapy and investigate the frequency of reactivation in patients with previous HBV infection. Methods: The charts of 275 patients who were followed up in the rheumatology department and used biological drug therapy were examined to evaluate the HBsAg, anti-HBc IgG, and anti-HBs test results. The frequency of reactivation was investigated by examining the HBV DNA test results before and after the biological drug therapy and the alanin aminotransferase test results were checked throughout the biological drug therapy in anti-HBc IgG-positive patients. Results: Among the patients, HBsAg was positive in 0.4%, anti-HBs in 34.4%, and anti-HBc IgG in 25.1%. The reactivation frequency was investigated in 53 biological drug therapies applied in 41 patients. The use of prophylactic antiviral drugs, where reactivation was evaluated, was found as 28.6% in TNF inhibitors, 100% in rituximab, 75.0% in tofacitinib, 0% in tocilizumab, 50% in abatacept, and 0% in secukinumab. Reactivation was detected in one of the fifty-three biological drug therapies. The reactivation case was a patient with isolated anti-HBc IgG and initial HBV DNA tests positive, using tocilizumab and cortisone, and not using entecavir prophylactic treatment regularly. Conclusions: The frequency of previous HBV infection is high in patients using biological therapy. Although prophylactic antiviral drug therapy for HBV has not been used frequently during the use of biological drug therapies other than rituximab in anti-HBc IgG positive patients, reactivation is rare. The risk of reactivation may be low in those receiving tofacitinib and secukinumab therapy and high in those receiving tocilizumab therapy.